

## **EISAI TO LAUNCH BOTULINUM TOXIN TYPE B NEUROMUSCULAR-BLOCKING AGENT NERBLOC® INTRAMUSCULAR INJECTION 2500 UNITS IN JAPAN**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that it will launch NerBloc® Intramuscular Injection 2500 Units (botulinum toxin type B, “NerBloc”), a neuromuscular-blocking agent, in Japan on March 27 as a treatment for cervical dystonia.

Botulinum toxin type B is a protein produced by the anaerobic bacterium *Clostridium botulinum* type B. By acting specifically on motor nerve terminals at the neuromuscular junction, it inhibits the release of acetylcholine from the cholinergic nerve endings and exhibits muscle relaxant effects. Eisai acquired the

**[Notes to editors]**

**1. NerBloc® Product Outline**

- 1) Product Name: NerBloc® Intramuscular Injection 2500 Units
- 2) Generic Name: Botulinum toxin type B
- 3) Indications and Usage: Cervical dystonia
- 4) Dosage and Administration: Adults should be administered botulinum toxin type B in accordance with the following dosages by intramuscular injection into the tonic muscle.\* If multiple muscles are affected, dosage should be divided among affected muscles.
- The recommended total initial dose of NerBloc is 2500 units or 5000 units
- If effects are insufficient or symptoms reoccur, patients may be administered a maximum subsequent dose of 10000 units. However, subsequent dosing should not take place within two months of initial dose.
- \*Main tonic muscle: sternocleidomastoid, scalene, trapezius, levator scapulae, splenius capitis, semispinalis capitis
- 5) Listed Price: NerBloc® Intramuscular Injection 2500 Units  
28,902 yen per vial containing 2500 units